Cefepime and mortality: a real issue?

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Oncology

Background:

• Cefepime, a fourth-generation cephalosporin, is widely used for empirical treatment of neutropenic fever due to its broad antimicrobial spectrum.
• Randomized controlled trials have previously established the efficacy and safety of cefepime for neutropenic fever.
• Recent meta-analyses have raised concerns, indicating a potential increase in all-cause mortality associated with cefepime use.

Purpose of the Study:

• To critically evaluate the conflicting evidence regarding cefepime's use in neutropenic fever.
• To address the methodological and clinical uncertainties stemming from recent meta-analyses.
• To provide a balanced perspective on the continued use of cefepime for this indication.

Main Methods:

• Review and analysis of existing randomized controlled trials on cefepime for neutropenic fever.
• Critical appraisal of recent meta-analyses reporting increased all-cause mortality with cefepime.
• Discussion of potential confounding factors and limitations in the existing data.

Main Results:

• Established efficacy and safety of cefepime in prior clinical trials for neutropenic fever.
• Identification of potential biases and limitations within recent meta-analyses.
• Highlighting the need for careful consideration of patient populations and study methodologies.

Conclusions:

• Despite recent concerns, cefepime remains a valuable option for empirical treatment of neutropenic fever.
• Methodological issues in recent meta-analyses may have influenced their findings.
• Further rigorous clinical analyses are warranted to definitively assess the risk-benefit profile of cefepime in neutropenic fever.